• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ORISE GEL; SUBMUCOSAL INJECTION AGENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ORISE GEL; SUBMUCOSAL INJECTION AGENT Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Granuloma (1876)
Event Date 05/01/2023
Event Type  Injury  
Manufacturer Narrative
Block b3: the exact date of the event is unknown.The provided event date was chosen as a best estimate based on the date that the manufacturer became aware of the event.Block d4 and h4: the complainant was unable to provide the suspect device lot number; therefore, the lot expiration and device manufacture dates are unknown.Block g3: literature source journal article: rex dk, lahr re.The demise of orise, a submucosal lifting agent for endoscopic resection.Ame case rep 2023;7:11.Doi: 10.21037/acr-23-15 block h6: impact code f19 captures the reportable event of surgical intervention.
 
Event Description
Boston scientific corporation became aware of an event related to orise gel from an editorial ''the demise of orise, a submucosal lifting agent for endoscopic resection'' written by douglas rex., md and rachel lahr.The article mentions a monthly live web-based course on endoscopic mucosal resection (emr) procedures broadcasted from the author's center, where an unknown physician describes a related story from their home institution.The case involved submucosal distortion observed in a rectal emr scar following the use of orise injection.This distortion raised concerns about potential submucosal tumor growth, leading to surgical resection.However, the resected specimen did not show any cancerous growth, but rather exhibited an accumulation of eosinophilic material and multi-nucleated giant cells, indicative of an orise reaction.These changes, known as ''lifting granuloma,'' highlight the significance of submucosal distortion in emr scars, as it can have important adverse clinical outcomes.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ORISE GEL
Type of Device
SUBMUCOSAL INJECTION AGENT
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
BOSTON SCIENTIFIC LIMITED
model farm road
cork
EI  
Manufacturer Contact
carole morley
300 boston scientific way
marlborough, MA 01752
5086834015
MDR Report Key17167645
MDR Text Key317631370
Report Number3005099803-2023-03352
Device Sequence Number1
Product Code PLL
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Health Professional,Company Representative
Reporter Occupation Physician
Remedial Action Recall
Type of Report Initial
Report Date 06/20/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 05/25/2023
Initial Date FDA Received06/20/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Removal/Correction Number92970101-FA
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-